While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Context Although a number of studies have demonstrated the importance of constitutively
active androgen receptor variants (AR-Vs) in prostate cancer, questions still remain about …

Prostate cancer cells demonstrate a remarkable “addiction” to androgen receptor (AR)
signaling in all stages of disease progression. As such, suppression of AR signaling remains …

As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form,
genetic and epigenetic adaptation, clonal selection, and evolution of the tumor …

Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …

Resistance to the latest advanced prostate cancer therapies, including abiraterone and
enzalutamide, is associated with increased expression of constitutively active androgen …

Androgen receptor splice variants (AR-Vs)—which are expressed in castration-resistant
prostate cancer (CRPC) cell lines and clinical samples—lack the C-terminal ligand-binding …

The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical
landscape of prostate cancer treatment. Both drugs were designed to further suppress …

Many therapeutic options are now available for men with metastatic castration-resistant
prostate cancer (mCRPC), including next-generation androgen receptor axis-targeted …

The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology
is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen …